Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Antisense Therapeutics begins multiple-dose stage of phase I ATL-1103 trial

Sep. 14, 2011

Ampla Pharmaceuticals describes novel IL-1 beta inhibitors

Sep. 14, 2011

Studies evaluate GFT-505 in models of NAFLD/NASH

Sep. 13, 2011

BioSante Pharmaceuticals completes pharmacokinetic study of LibiGel

Sep. 13, 2011

Novel IL-1 beta inhibitors presented by Ampla Pharmaceuticals

Sep. 13, 2011

Long-term phase II data presented on eliglustat in type 1 Gaucher's disease

Sep. 13, 2011

Repros Therapeutics to submit IND for vaginal formulation of Proellex

Sep. 12, 2011

Takeda initiates phase III program for TAK-875 in Japan

Sep. 12, 2011

Novel IL-1 beta inhibitors disclosed by Ampla Pharmaceuticals

Sep. 12, 2011

Long-term safety of alipogene tiparvovec evaluated in patients with lipoprotein lipase deficiency

Sep. 12, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...